Ambiguity, Ambivalence, and Apprehensions of Taking HIV-1 Pre-Exposure Prophylaxis among Male Couples in San Francisco: A Mixed Methods Study

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Saberi, Parya ^a   Gamarel, Kristi E ^b   Neilands, Torsten B ^a   Comfort, Megan ^c   Sheon, Nicolas ^a   Darbes, Lynae A ^a   Johnson, Mallory O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AMBIGUITY; AMBIVALENCE; ANUS INTERCOURSE; ARTICLE; COMMUNITY CARE; COMPREHENSION; CROSS-SECTIONAL STUDY; HEALTH BEHAVIOR; HEALTH SURVEY; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HIV EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; MALE; MALE HOMOSEXUAL; PATIENT ATTITUDE; POST EXPOSURE PROPHYLAXIS; PRE EXPOSURE PROPHYLAXIS; PROPHYLAXIS; QUALITATIVE RESEARCH; RISK ASSESSMENT; UNITED STATES; UNSAFE SEX; VIRUS LOAD;

CROSS-SECTIONAL STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HOMOSEXUALITY, MALE; HUMANS; INTERVIEWS AS TOPIC; MALE; PRIMARY PREVENTION; REGRESSION ANALYSIS; SAN FRANCISCO;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869142949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050061     Document Type: Article

References (31)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine 363: 2587-2599.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England journal of medicine 367: 399-410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. The New England journal of medicine 367: 423-434.
5. Microbicide Trials Network (2011) Microbicide trials network statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women.
6. Microbicide Trials Network (2011) Microbicide trials network statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women.
7. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine 367: 411-422.
8. Barash EA, Golden M, (2010) Awareness and Use of HIV Pre-Exposure Prophylaxis Among Attendees of a Seattle Gay Pride Event and Sexually Transmitted Disease Clinic. Aids Patient Care and Stds 24: 689-691.
9. Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, et al. (2006) Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. Jaids-Journal of Acquired Immune Deficiency Syndromes 43: 376-377.
10. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, et al. (2008) Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. Jaids-Journal of Acquired Immune Deficiency Syndromes 47: 241-247.
11. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH, (2009) Preexposure Antiretroviral Prophylaxis Attitudes in High-Risk Boston Area Men Who Report Having Sex With Men: Limited Knowledge and Experience but Potential for Increased Utilization After Education. Jaids-Journal of Acquired Immune Deficiency Syndromes 50: 77-83.
12. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 48: 806-815.
13. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839.
14. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ, (2008) The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. Plos One 3: e2077.
15. Abbas UL, Anderson RM, Mellors JW, (2007) Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. Plos One 2: e875.
16. Johnson MO (2006) Relationship Factors and HIV Treatment Adherence (NIH project number R01NR010187). National Institute of Nursing Research.
17. Johnson MO, Dilworth SE, Taylor JM, Darbes LA, Comfort ML, et al. (2011) Primary Relationships, HIV Treatment Adherence, and Virologic Control. Aids and Behavior.
18. Patton MQ (2002) Qualitative Research and Evaluation Methods. Thousand Oaks, CA: Sage Publications.
19. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression. New York, NY: John Wiley & Sons.
20. Harrell FE Jr. (2001) Regression Modeling Strategies. New York, NY: Springer-Verlag.
21. Thomas DR, (2006) A general inductive approach for analyzing qualitative evaluation data. American Journal of Evaluation 27: 237-246.
22. Miles MB, Huberman AM (1994) Qualitative data analysis: An expanded sourcebook Thousand Oaks, CA: Sage Publications.
23. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, et al. (2012) Sexual Risk Behaviors and Acceptability of HIV Pre-Exposure Prophylaxis Among HIV-Negative Gay and Bisexual Men in Serodiscordant Relationships: A Mixed Methods Study. Aids Patient Care and Stds 26: 87-94.
24. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, et al. (2008) Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 35: 1002-1008.
25. Cassell MM, Halperin DT, Shelton JD, Stanton D, (2006) Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 332: 605-607.
26. Eaton LA, Kalichman S, (2007) Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 4: 165-172.
27. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, et al. (2011) Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. Plos One 6: e23688.
28. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, et al. (2007) Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2: e27.
29. Buchbinder S, Glidden D, McConnell J, Casapia M, Montoya-Herrera O, et al. (2012) Prioritizing PrEP among MSM for Greatest Efficacy: An Analysis of the iPrEx Data (Paper #1066). Conference on Retroviruses and Opportunistic Infections. Seattle, WA.
30. Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, et al. (2012) A Qualitative Study of Provider Thoughts on Implementing Pre-Exposure Prophylaxis (PrEP) in Clinical Settings to Prevent HIV Infection. Plos One 7.
31. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.